Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Abstract There is still a need for safe, efficient, and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) th...
Full description
Bibliographic Details
| Main Authors: |
Samuel Ponce-de-León,
Martha Torres,
Luis Enrique Soto-Ramírez,
Juan José Calva,
Patricio Santillán-Doherty,
Dora Eugenia Carranza-Salazar,
Juan Manuel Carreño,
Claudia Carranza,
Esmeralda Juárez,
Laura E. Carreto-Binaghi,
Luis Ramírez-Martínez,
Georgina Paz De la Rosa,
Rosalía Vigueras-Moreno,
Alejandro Ortiz-Stern,
Yolanda López-Vidal,
Alejandro E. Macías,
Jesús Torres-Flores,
Oscar Rojas-Martínez,
Alejandro Suárez-Martínez,
Gustavo Peralta-Sánchez,
Hisaaki Kawabata,
Irene González-Domínguez,
José Luis Martínez-Guevara,
Weina Sun,
David Sarfati-Mizrahi,
Ernesto Soto-Priante,
Héctor Elías Chagoya-Cortés,
Constantino López-Macías,
Felipa Castro-Peralta,
Peter Palese,
Adolfo García-Sastre,
Florian Krammer,
Bernardo Lozano-Dubernard |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Portfolio
2023-05-01
|
|---|
| Series: | npj Vaccines
|
|---|
| Online Access: | https://doi.org/10.1038/s41541-023-00662-6
|
|---|